Compare CLLS & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLLS | PROF |
|---|---|---|
| Founded | 1999 | N/A |
| Country | France | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 299.0M | 230.4M |
| IPO Year | 2007 | N/A |
| Metric | CLLS | PROF |
|---|---|---|
| Price | $4.40 | $7.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $8.00 | ★ $11.00 |
| AVG Volume (30 Days) | 133.9K | ★ 142.9K |
| Earning Date | 11-07-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $82,551,000.00 | $14,297,000.00 |
| Revenue This Year | $32.58 | $64.23 |
| Revenue Next Year | N/A | $113.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 129.04 | 67.94 |
| 52 Week Low | $1.10 | $3.76 |
| 52 Week High | $5.48 | $7.99 |
| Indicator | CLLS | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 49.34 | 63.62 |
| Support Level | $4.47 | $7.19 |
| Resistance Level | $5.45 | $7.95 |
| Average True Range (ATR) | 0.30 | 0.41 |
| MACD | -0.12 | 0.06 |
| Stochastic Oscillator | 31.17 | 81.72 |
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.